Replies to post #16557 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Today’s Confidential Treatment Order is a MNTA request that the SEC leave redactions in the MNTA-MYL partnership agreement filed as an exhibit to the 1Q16 10-Q (https://www.sec.gov/Archives/edgar/data/1235010/000110465916118813/a16-6503_1ex10d2.htm ). This is MNTA’s second iteration regarding redactions of this agreement.

This is a routine process—it doesn’t signify anything in particular.